Monday will kick off a busy week for data on Wall Street, with the latest manufacturing ISM index due at 10 a.m. ET.» Read More
Multi-level marketing is a big business, but one critic says it's also a big lie.
Oct 31- Nu Skin Enterprises Inc raised its full-year forecast for the sixth time this year, encouraged by strong demand for its new anti-ageing and body spa products under the ageLOC brand. Nu Skin shares rose 11 percent to $46.70 on the New York Stock Exchange on Wednesday morning.
Oct 31- Nu Skin Enterprises Inc's quarterly results handily beat Wall Street expectations on strong performance of its anti-ageing and nutritional supplement businesses in China, prompting the company to raise its full-year forecast for the sixth time.
--Abiomed Inc rescheduled second-quarter conference call to Nov. 1 at 8 am Eastern Time. --Accelrys Inc rescheduled third-quarter results to Oct. 31, after market. Its conference call will be held on Nov. 1, 9.30 am Eastern Time.
Oct 26- Individual donors to U.S. presidential candidates can contribute up to $2,500 for the state-by-state party nominating contests and another $2,500 for the general election.
Oct 2- Nautilus Minerals Inc:.
Shares of Nu Skin got hammered earlier in the week after a report from a well-known short-selling firm Citron Research came out questioning the viability of the company's operations in China. Andrew Left, Citron Research, and Bill Schmitz, Deutsche Bank senior research analyst, discuss.
Andrew Left, Manager, Citron Research, alleges that Nu Skin is illegally running a pyramid scheme in China. He adds that it's unclear if Chinese regulators are investigating his claims against the company.
Take a look at some of Tuesday's midday movers:
Herbalife, whose stock tumbled last week after hedge fund manager David Einhorn asked a few questions on the company’s earnings call, is no stranger to controversy. Herb Greenberg sees some reasons to worry.
Jim Cramer and his researcher, Nicole Urken, discuss why Avon’s management situation needs a serious makeover.
Tim Ramey, D.A. Davidson & Co., discusses why the seller of anti-aging products has delivered such strong earnings results.
When it comes to combating financial markets that all seem to move in unison, the options are getting so limited that some are questioning whether stock picking is a dying art.
Most market participants expect the Federal Reserve to resume buying assets, and do so in a sizeable way, according to a CNBC survey. How will the move affect markets? Jim Lacamp, portfolio manager at Macropotfolio Advisors and Craig Peckham, managing director and equity product strategist at Jefferies shared their outlooks.
The Lightning Round is extended in this CNBC.com exclusive feature.